Lupus nephritis: a modern treatment paradigm
Journal Title: Нирки - Year 2018, Vol 7, Issue 2
Abstract
Lupus nephritis is the most common and life-threatening manifestation of systemic lupus erythematosus (SLE) and continues to cause a high percentage of terminal renal failure. The modern treatment of lupus nephritis, as well as new therapeutic strategies, is described in this review. Diagnosis of kidney damage in SLE (lupus nephritis), according to the recommendations of ACR, is based on the following criteria: clinical and laboratory manifestations in the form of proteinuria > 0.5 g/day (or more than 3 “+” when using test strips) and/or the presence of cellular clusters, including clusters of erythrocytes and cylinders (hemoglobin, granular, tubular or mixed). Additional criteria are the results of histological examination of the kidney biopsy with confirmation of the presence of immune complex kidneys damage characteristic of lupus nephritis. The management of lupus nephritis patients consists of two successive phases: initial (induction) and supporting, when combinations of glucocorticoids and immunosuppressors are used. During the induction phase, intensive treatment with glucocorticoids in combination with other immunosuppressants is carried out to rapidly suppress the immune complex renal inflammation and to stop the development of their damage. The aim of this approach and the main task of induction therapy are the restoration of renal function and induction of remission by monitoring the immunological activity of the process. Supportive therapy is used to fix remission and to prevent exacerbations by using drugs or treatment regimens with less risk of complications. Despite the disappointing results of several recent studies, new methods of treatment aimed at various immunological pathways are being actively studied in lupus nephritis. The most promising direction is therapy aimed at B-cells. Deepening understanding of the pathogenesis of lupus nephritis, developing new treatments and optimizing the design of clinical trials will ensure the successful development and introduction of new drugs for lupus.
Authors and Affiliations
I. Yu. Golovach
Keywords
Related Articles
- EP ID EP280847
- DOI 10.22141/2307-1257.7.2.2018.127399
- Views 108
- Downloads 0
Moxonidine in the treatment of chronic kidney disease associated with hypertension
Kidney disease pathogenesis is closely related to essential or secondary hypertension. Treatment of chronic kidney disease associated with hypertension requires a comprehensive causal and pathogenetic therapy. The topic...
Functional Renal Reserve: Physiological Value of Renal Reserve and Substantiation of the Method of Its Determination
In the article the authors have substantiated and shown the mechanisms of functional renal reserve actuation and its physiological meaning. There is dwelt the method of functional renal reserve determination. It was test...
Cystatin C and chronic kidney disease in children
Background. Determination of diagnostically significant values of serum concentration of cystatin C in combination with the estimated glomerular filtration rate (GFR) gives clinicians an advantage in clearly differentiat...
Hemostatic System and its Regulation in Disorders of Renal Function
In various violations of kidney function, there is a change in the hemostatic system, which can manifest itself in the form of thrombosis or bleedings. In these processes, vascular endothelium, platelets, plasma proteins...
Evaluation of Therapeutic and Preventive Potential of Canephron N in Acute Cystitis in Children: Results of Clinical Study
.